George Farmer
Stock Analyst at Scotiabank
(1.71)
# 3,210
Out of 4,944 analysts
70
Total ratings
31.58%
Success rate
-9.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by George Farmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Maintains: Sector Outperform | $30 → $10 | $1.72 | +481.40% | 4 | Aug 6, 2025 | |
| ACLX Arcellx | Maintains: Sector Outperform | $93 → $133 | $70.90 | +87.59% | 3 | Jul 31, 2025 | |
| INMB INmune Bio | Downgrades: Sector Underperform | $23 → $0.6 | $2.56 | -76.56% | 3 | Jul 1, 2025 | |
| URGN UroGen Pharma | Maintains: Sector Outperform | $23 → $47 | $20.11 | +133.71% | 1 | Jun 13, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Sector Perform | $16 → $17 | $13.45 | +26.39% | 4 | May 6, 2025 | |
| TARA Protara Therapeutics | Initiates: Sector Outperform | $12 | $3.26 | +268.10% | 1 | Apr 16, 2025 | |
| TPST Tempest Therapeutics | Downgrades: Sector Perform | $91 → $9 | $9.34 | -3.64% | 4 | Apr 10, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Sector Outperform | $3.15 → $1.4 | $0.08 | +1,690.28% | 2 | Mar 21, 2025 | |
| JANX Janux Therapeutics | Maintains: Sector Perform | $62 → $41 | $24.96 | +64.26% | 4 | Feb 28, 2025 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Sector Outperform | $47 → $52 | $25.76 | +101.86% | 4 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $78 → $80 | $58.30 | +37.22% | 8 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $244 → $224 | $135.19 | +65.69% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $102 | $41.27 | +147.15% | 1 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $18 → $10 | $6.49 | +54.08% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $439 → $715 | $646.60 | +10.58% | 5 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $20 → $23 | $7.23 | +218.12% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $20 | $3.14 | +536.94% | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $70 → $76 | $36.93 | +105.79% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $13 | $3.12 | +316.67% | 1 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $109 | $26.89 | +305.36% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $94 → $87 | $85.85 | +1.34% | 5 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $2.33 | +1,316.31% | 1 | Oct 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $0.83 | +4,723.34% | 1 | Jul 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $27 | $38.49 | -29.85% | 3 | May 6, 2020 |
Biomea Fusion
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $30 → $10
Current: $1.72
Upside: +481.40%
Arcellx
Jul 31, 2025
Maintains: Sector Outperform
Price Target: $93 → $133
Current: $70.90
Upside: +87.59%
INmune Bio
Jul 1, 2025
Downgrades: Sector Underperform
Price Target: $23 → $0.6
Current: $2.56
Upside: -76.56%
UroGen Pharma
Jun 13, 2025
Maintains: Sector Outperform
Price Target: $23 → $47
Current: $20.11
Upside: +133.71%
Syndax Pharmaceuticals
May 6, 2025
Maintains: Sector Perform
Price Target: $16 → $17
Current: $13.45
Upside: +26.39%
Protara Therapeutics
Apr 16, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $3.26
Upside: +268.10%
Tempest Therapeutics
Apr 10, 2025
Downgrades: Sector Perform
Price Target: $91 → $9
Current: $9.34
Upside: -3.64%
Adaptimmune Therapeutics
Mar 21, 2025
Maintains: Sector Outperform
Price Target: $3.15 → $1.4
Current: $0.08
Upside: +1,690.28%
Janux Therapeutics
Feb 28, 2025
Maintains: Sector Perform
Price Target: $62 → $41
Current: $24.96
Upside: +64.26%
NewAmsterdam Pharma Company
Feb 27, 2025
Maintains: Sector Outperform
Price Target: $47 → $52
Current: $25.76
Upside: +101.86%
Feb 20, 2025
Maintains: Sector Perform
Price Target: $78 → $80
Current: $58.30
Upside: +37.22%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $244 → $224
Current: $135.19
Upside: +65.69%
Feb 13, 2025
Initiates: Sector Outperform
Price Target: $102
Current: $41.27
Upside: +147.15%
Jan 8, 2025
Maintains: Sector Perform
Price Target: $18 → $10
Current: $6.49
Upside: +54.08%
Nov 5, 2024
Upgrades: Sector Outperform
Price Target: $439 → $715
Current: $646.60
Upside: +10.58%
Oct 18, 2024
Maintains: Sector Outperform
Price Target: $20 → $23
Current: $7.23
Upside: +218.12%
Sep 30, 2024
Initiates: Sector Outperform
Price Target: $20
Current: $3.14
Upside: +536.94%
Aug 12, 2024
Maintains: Sector Outperform
Price Target: $70 → $76
Current: $36.93
Upside: +105.79%
Mar 14, 2024
Initiates: Sector Outperform
Price Target: $13
Current: $3.12
Upside: +316.67%
Nov 17, 2020
Downgrades: Market Perform
Price Target: $109
Current: $26.89
Upside: +305.36%
Nov 6, 2020
Maintains: Market Perform
Price Target: $94 → $87
Current: $85.85
Upside: +1.34%
Oct 27, 2020
Initiates: Outperform
Price Target: $33
Current: $2.33
Upside: +1,316.31%
Jul 20, 2020
Initiates: Outperform
Price Target: $40
Current: $0.83
Upside: +4,723.34%
May 6, 2020
Maintains: Market Perform
Price Target: $20 → $27
Current: $38.49
Upside: -29.85%